Beneath the Surface: Exploring spironolactone’s place in acne management
Click Here to Manage Email Alerts
Beneath the Surface is a video series in which Joel M. Gelfand, MD, MSCE, Healio Dermatology Chief Medical Editor, discusses hot topics in the field with leading experts.
In this edition, Gelfand, who is also the James J. Leyden Professor of Clinical Investigation and professor of dermatology and epidemiology at University of Pennsylvania’s Perelman School of Medicine, discusses new research into spironolactone with John Barbieri, MD, MBA, assistant professor at Harvard Medical School, director of the advanced acne therapeutics clinic at Brigham and Women’s Hospital and co-chair of the AAD Acne Guidelines Work Group.
Studies have found spironolactone to be more efficacious than both placebo and doxycycline in the treatment of acne, with a 10 mg daily dose showing a low side effect profile.
An ongoing NIH-funded trial is also continuing to look at how spironolactone compared with doxycycline, while also looking at how the two drugs affect the microbiome.
“Hormonal therapies like spironolactone can work in any population with acne,” Barbieri said. “So, we should be open minded about who we consider offering that treatment to. I think any female patient can potentially benefit from spironolactone and studies have shown that even in adolescents it can be useful.”
Collapse
Healio Interviews
Read more about
Click Here to Manage Email Alerts